Skip to main content

Table 2 Modulation of costimulatory and coregulatory molecule expression by iv-SIL

From: Immunomodulating effects of the anti-viral agent Silibinin in liver transplant patients with HCV recurrence

% (mean ± SD)

pDC

 

mDC

 
 

Pre

Post

p

Pre

Post

p

HLA-DR

92.9 ± 5.5

90.9 ± 7.8

0.1600

93.7 ± 9.7

87.5 ± 17.3

0.1035

CD83

45.9 ± 16.2

50.3 ± 20.6

0.6231

26.7 ± 10.7

37.7 ± 23.1

0.1793

CD86

59.8 ± 14.2

65.6 ± 10.9

0.2250

90.6 ± 5.3

87.8 ± 14.0

0.6306

ICOSL

45.1 ± 18.3

52.2 ± 12.3

0.2758

29.6 ± 12.6

36.2 ± 7.2

0.0122

PD-L1

18.9 ± 11.2

25.5 ± 12.0

0.0883

10.6 ± 6.8

17.0 ± 10.6

0.0938

HLA-G

26.2 ± 8.1

36.19 ± 8.6

0.0449

45.8 ± 10.3

50.8 ± 11.6

0.3614

IL-T4

97.3 ± 2.7

96.8 ± 6.1

0.7293

89.3 ± 5.7

91.7 ± 5.6

0.3397

CD39

16.2 ± 8.7

22.1 ± 9.4

0.0377

69.4 ± 7.6

74.0 ± 10.7

0.3064

  1. PBMC were analyzed before and after iv-SIL treatment by flow cytometry, as described in the “Methods” section, and the overall analysis of HLA-DR, CD83, CD86, ICOSL, PD-L1, HLA-G, IL-T4, and CD39 expression (%, mean SD) by mDC and pDC is presented. Italicized values denote significance